The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Therapeutics, Inc. COM 00461U105 59,687 3,399,034 SH   SOLE   3,399,034 0 0
Cymabay Therapeutics, Inc. COM 23257D103 7,792 1,787,094 SH   SOLE   1,787,094 0 0
Cytokinetics Incorporated COM 23282W605 10,788 545,101 SH   SOLE   545,101 0 0
Decibel Therapeutics, Inc. COM 24343R106 2,560 297,711 SH   SOLE   297,711 0 0
Kinnate Biopharma Inc. COM 49705R105 225,156 9,671,643 SH   SOLE   9,671,643 0 0
Kura Oncology, Inc. COM 50127T109 38,571 1,849,947 SH   SOLE   1,849,947 0 0
Lyell Immunopharma, Inc. COM 55083R104 215,703 13,282,181 SH   SOLE   13,282,181 0 0
Nurix Therapeutics, Inc. COM 67080M103 31,990 1,205,798 SH   SOLE   1,205,798 0 0
Olema Pharmaceuticals, Inc. COM 68062P106 9,570 342,030 SH   SOLE   342,030 0 0
Pharvaris N.V. COM N69605108 60,770 3,261,926 SH   SOLE   3,261,926 0 0
Quantum-Si Incorporated COM CL A 74765K105 54,724 4,463,619 SH   SOLE   4,463,619 0 0
Relay Therapeutics, Inc. COM 75943R102 20,358 556,380 SH   SOLE   556,380 0 0
Tempest Therapeutics, Inc. COM 87978U108 2,127 190,212 SH   SOLE   190,212 0 0